Načítá se...
Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
Oral cabozantinib tablets (Cabometyx(®)) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated in the development of RCC. The previously approved indicatio...
Uloženo v:
| Vydáno v: | Drugs Ther Perspect |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6323107/ https://ncbi.nlm.nih.gov/pubmed/30679901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40267-018-0547-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|